Octimet Oncology N.V.   Report issue

For profit Phase 2
Founded: Beerse Belgium (2006)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT03138083
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

omo-1 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1